Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Allogene Therapeutics

Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2018 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$562M
Market cap · Apr/2026

Investors

5 investors on Allogene Therapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 5 investors entered at this stage
Pfizer
TPG
Two River
Vida Ventures
Perceptive Advisors

Global footprint

Where Allogene Therapeutics has talent and traffic

AI talent share
1.4% of workforce is AI talent
(3 of 208 staff)
Core AI10.48%
Other AI20.96%
Non-AI workforce20598.56%
Web traffic by country
19K monthly visits
across markets
🇺🇸 United States64.2%
🇨🇦 Canada12.1%
🇮🇳 India6.8%
🇬🇧 United Kingdom6.3%
🇪🇸 Spain5.3%
Top 5 markets shown

Patent intelligence

$64M patent portfolio · 71 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value
$64M
11.4% of market cap · 12.1× smaller than top peer BioNTech ($780M)
71 active patent families
Where Allogene Therapeutics innovates Molecular biologyCAR - Chimeric antigen receptorIMMUNOLOGIC CELLSCell biologyAntigen receptors
Above peer median on Legal, Market, Economic, Technology

Quality vs same-sector peers

Allogene Therapeutics on the five Patsnap quality dimensions

Allogene Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Allogene Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Allogene Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Allogene Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo